



JOINT PROGRAMMING
INITIATIVE
ON ANTIMICROBIAL
RESISTANCE

A light blue world map is visible in the background of the text area. Overlaid on the map are several colorful icons representing antibiotics: a blue capsule, an orange capsule, a green capsule, and a yellow capsule.

INTERNATIONAL
COLLABORATION
OPPORTUNITIES

Laura Marin
Head of JPIAMR Secretariat

Brussels, 24 Nov. 2016

www.jpiaamr.eu



WE MUST ACT NOW!

With the current spread of antimicrobial resistance we need to invest in research. For example, US funding into AMR research is almost 16 times lower than funding available for cancer research.

BY 2050



CANCER
8.2
MILLION
DEATHS
PER YEAR



AMR
10
MILLION
DEATHS
PER YEAR

What is about



What: JPIAMR is an international platform of 22 member countries to define a common vision, a strategic research agenda and joint planning as well as implementation of national research programmes


Aim: Reduce the burden of non treatable infection diseases by resistance bacteria **By** preventing infections and developing new or better treatments

THROUGH:


- Alignment of research plans and AMR policies
- Aligning resources
- Coordination of funding strategies
- Supporting scientific activities at international level

To provide evidence-based solutions at the level of:
research policy; at public health; veterinarian; agriculture

ALIGNMENT



Source: Wellcome Trust AMR report, 2016



Source: JPIAMR SRA, 2014

ALIGNMENT OF NATIONAL AND INTERNATIONAL POLICIES AND RESEARCH PROGRAMMES THROUGH THE STRATEGIC RESEARCH AGENDA

JPIAMR'S ADDED VALUE

ALIGNS INTERNATIONAL
RESOURCES TO ENABLE
JOINT ACTIONS IN AREAS
OF UNMET NEEDS


SHARED COMMON STRATEGIC
RESEARCH AGENDA TO ALIGN
NATIONAL PRIORITIES AND
COORDINATED ACTIONS

PROVIDES
NETWORKING
OPPORTUNITIES

COLLABORATIVE
PLATFORM TO TAKE
THE AMR COMBAT
FROM AWARENESS
TO ACTION

AVOIDS
DUPLICATION AND
FRAGMENTATION
OF RESEARCH

SUPPORTING
INTERNATIONAL
RESEARCH AND
FACILITATING ITS
TRANSLATION TO
INDUSTRY AND
POLICY



WORKING TOGETHER



22 COUNTRIES
TO DATE HAVE JOINED FORCES
TO DEFINE A COMMON VISION


ARGENTINA
CANADA
BELGIUM
CZECH REPUBLIC
DENMARK
ESTONIA
FINLAND
FRANCE
GERMANY
GREECE
ISRAEL
ITALY
JAPAN
THE NETHERLANDS
NORWAY
POLAND
ROMANIA
SPAIN
SWEDEN
SWITZERLAND
TURKEY
THE UNITED KINGDOM

22 countries to date have joined forces to define a common vision, a strategic research agenda and joint planning as well as implementation of national research programmes

Key partnerships:

- THE WORLD HEALTH ORGANISATION (WHO)
- Transatlantic US-EU Task Force on AMR (TATFAR)
- ASEAN
- EU Action Plan – research deployment
- G7, G20, UN AMR declarations – research deployment

Type of activities - cooperation



Implementation of the 6 topic pillars of the AMR Strategic Research Agenda, through:

- Scoping or strategic workshops
 - to identify future joint actions
 - to map the landscape and identify knowledge gaps
 - to bring together experts from diverse fields

Examples:

- Transmission Dynamics, Berlin
- EU-US New Frontiers in Antibacterial Resistance Research, Stockholm
- EARLY DISCOVERY OF NEW ANTIBIOTICS, Paris
- Joint calls (4 joint calls, 55 M eur; 50 funded projects)
 - 2017: Prevention and Interventions call, Research Networks call
 - 2018: Surveillance call; New Compounds identification call
- Intergovernmental meetings: support alignment of one health programmes
- Participate in the JPIAMR [Virtual Institute](#)
- *Capacity building program and research exchange*
 - 2017: Fellowship programme

Plans 2018-2020



- Set up a Virtual institute.
- Issue a Prevention call in 2017.
- Issue a Fellowship grant call in 2017-18.
- Issue a joint call in Surveillance in 2018 (topic identification under development)
- Issue a joint call in new Compounds identification in 2018 (topic identification under development)
- Set up a new Eranet cofund in 2019 in the area of Interventions (topic identification under development)
- Issue several policy calls to set new Working Groups/Research Networks
- Reinforce discussions with industry regarding bridging the gap between pre-clinical and clinical: feeding the antibiotic pipeline.
- Update the Strategic Research Agenda – defining new research priorities.
- Active involvement in the SG Sante AMR Joint Action to define together the research needs of the public health authorities.
- Work internationally in the potential development of an AMR Global Fund.
- Set up high profile scientific workshops.

POLICY IMPACT

STRUCTURAL IMPACT IN RESEARCH: SRA One health approach covering human and animal health and environment: affects the structure of the scientific community with cross-fertilization among scientific areas

- Funding knowledge gaps. Funding new types of projects/areas
- Funding research networks and policy networks (new scientific links, open possibilities new networks). Increase transnational collaboration
- Attract more researchers to the field.

POLICY IMPACT:

- AT POLICY LEVEL: alignment of funding among agencies (joint development of research priorities)
- AT NATIONAL LEVEL:
 - Support the development of national AMR plans (e.g. from 2 to 20 members have national plans) and
 - Alignment of the research elements inside the national plans (e.g. Sweden, Spain).
 - Set up new AMR national research programmes with new earmark funding (e.g. Norway, Sweden, NL, Switzerland)

IMPACT IN FUNDING LEVEL:

- Increase budget,
- Create national AMR research programmes aligned with SRA and joint JPIAMR co-funded programmes

POLITICAL IMPACT

POLITICAL IMPACT:

- AT GLOBAL LEVEL:
 - JPIAMR SRA mentioned at WHO AMR global action plan to develop a global research agenda. Global coordination capacity. Political output. G7
 - Global expansion more countries showing interest in JPIAMR (Japan, Argentina, S-A)
 - Coordination of the AMR funding programmes with Charities and Trusts
 - Bringing structure on AMR policy by structuring effect in the research area
- AT EU LEVEL:
 - Coordination of JPIAMR joint calls, H2020 programme and IMI programme in the area of AMR
 - More close alignment opportunities with the industry/IMI
 - Input in the Health council conclusions and on the EU AMR Action Plan
 - Work together with DG Sante JA on AMR bringing alignment of European health authorities priorities



GET INVOLVED.

The greatest value of participating in the JPIAMR's joint activities lies in the collaborative aspect of this initiative. This applies to JPIAMR's member organisations themselves as well as to the researchers who are funded by the initiatives activities.



**BECOME A NATIONAL MEMBER
COLLABORATE AS A PARTNER IN ACTIVITIES**



www.jpiamr.eu



@ JPIonAMR



secretariat.jpiamr@vr.se